Novartis receives FDA approval for Rhapsido® (remibrutinib), the only oral, targeted BTKi treatment for chronic spontaneous urticaria (CSU)

Why did OPEC+ decide to raise oil output? How will Japan’s new leader affect markets? What impact will the US government shutdown have? Why is California suing Trump over National Guard troops? How is Bitcoin reaching new record highs? What caused Rite Aid to close all stores? Why are layoffs looming amid the shutdown?

Novartis receives FDA approval for Rhapsido® (remibrutinib), the only oral, targeted BTKi treatment for chronic spontaneous urticaria (CSU)

novartis.com/news/media-releases/novartis-receives-fda-approval-rhapsido-remibrutinib-only-oral-targeted-btki-treatment-chronic-spontaneous-urticaria-csu

Ad hoc announcement pursuant to Art. 53 LR
- Rhapsido helps to inhibit release of histamine and proinflammatory mediators by targeting BTK, offering unique approach to CSU treatment1
- Well-controlled disease observed as fast as two weeks, with demonstrated safety profile that requires…

This story appeared on novartis.com, 2025-10-01 18:00:22.368000.